| Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Community Treatment for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + Gem/Cis for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELI-002 2P for cholangiocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Haic+tae + tislelizumab + surufatinib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PD-1antibody plus GEMOX for klatskin tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sequential cytoreductive intervention for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SOC plus trastuzumab and pembrolizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|